The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance

Diabetes Research and Clinical Practice

Volumn 94, Issue 1, 2011, Pages 71-76

  Lan, Jianjun ^a   Chen, Xiaoni ^a   Chen, Xiaoping ^a   Wang, Si ^a   Zhang, Xin ^a   Wu, Kai ^a   He, Sen ^a   Peng, Yong ^a   Jiang, Lingyun ^a   Li, Longxin ^a   Wan, Liyan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Amlodipine; Insulin resistance; Nondiabetic essential hypertension; Telmisartan; Visfatin

Indexed keywords

AMLODIPINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TELMISARTAN;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY;

AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROSPECTIVE STUDIES;

EID: 80054889018     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.05.039     Document Type: Article

References (30)

1. Araki S., Dobashi K., Kubo K., Kawagoe R., Yamamoto Y., Kawada Y., et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008, 16:384-388.
2. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
3. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994, 14:1431-1437.
4. American Diabetes Association Consensus development conference on insulin resistance. Diabetes Care 1998, 21(2):310-314.
5. Ferrannini E., Natali A., Bell P., Cavallo-Perin P., Lalic N., Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997, 100:1166-1173.
6. Haffner S., Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003, 108:1541-1545.
7. Sowers J.R. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004, 286:H1597-H1602.
8. Haider D.G., Schindler K., Schaller G., Prager G., Wolzt M., Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006, 91:1578-1581.
9. Davutoglu M., Ozkaya M., Guler E., Garipardic M., Gursoy H., Karabiber H., et al. Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly 2009, 139:22-27.
10. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007, 56:451-458.
11. Schmieder R.E. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005, 18:720-730.
12. Chu K.Y., Lau T., Carlsson P.O., Leung P.S. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006, 55:367-374.
13. Henriksen E.J., Jacob S., Kinnick T.R., Teachey M.K., Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001, 38:884-890.
14. Schulman I.H., Zachariah M., Raij L. Calcium channel blockers, endothelial dysfunction, and combination therapy. Aging Clin Exp Res 2005, 17:40-45.
15. Koyama Y., Kodama K., Suzuki M., Harano Y. Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens 2002, 15:927-931.
16. Alberti K.G., Zimmet P.Z. Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
17. Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
18. Nusken K.D., Nusken E., Petrasch M., Rauh M., Dotsch J. Preanalytical influences on the measurement of visfatin by enzyme immuno assay. Clin Chim Acta 2007, 382:154-156.
19. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412-419.
20. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000, 85:4426-4433.
21. Agueda M., Lasa A., Simon E., Ares R., Larrarte E., Labayen I. Association of circulating visfatin concentrations with insulin resistance and low-grade inflammation after dietary energy restriction in Spanish obese non-diabetic women: role of body composition changes. Nutr Metab Cardiovasc Dis 2010, (October). [Epub ahead of print].
22. Esteghamati A., Alamdari A., Zandieh A., Elahi S., Khalilzadeh O., Nakhjavani M., et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract 2010, (November). [Epub ahead of print].
23. Hug C., Lodish H.F. Visfatin: a new adipokine. Science 2005, 307:366-367.
24. Berndt J., Kloting N., Kralisch S., Kovacs P., Fasshauer M., Schön M.R., et al. Plasma visfatin concentrations and fat depet-specific mRNA expression in humans. Diabetes 2005, 54:2911-2916.
25. Kim J.A., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
26. Choi K.C., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., Kim S.G., et al. Effect of PPAR-a and -c agonist on the expression of visfatin, adiponectin, and TNF-a in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005, 336(3):747-753.
27. Storka A., Vojtassakova E., Mueller M., Kapiotis S., Haider D.G., Jungbauer A., et al. Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 2008, 38:820-826.
28. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARg-modulating activity. Hypertension 2004, 43:993-1002.
29. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2002, 25:626-640.
30. Yeckel C.W., Weiss R., Dziura J., Taksali S.E., Dufour S., Burgert T.S., et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004, 89:1096-1101.